| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Oncology, Markers, Clinical Correlates |
Department of Oncology and Neurosciences, University Gabriele D’Annunzio, 66100 Chieti, Italy [A. M.], and Departments of Oncology [G. Ber., F. B., G. Q., G. Bev.] and Surgery [A. C., C. A. A.], University of Pisa, 56100 Pisa, Italy
Patients with stage I non-small cell lung cancer (NSCLC) are typically treated with surgical resection alone. However, about one-third of such patients develop disease recurrence and die within 5 years after complete resection. The ability to predict recurrence could represent an important contribution to treatment planning. This study evaluates the presence of telomerase activity in tumor cells as a predictor of disease recurrence and cancer-related death after operation for stage I NSCLC patients. The activity of the telomerase enzyme was investigated by telomeric repeat amplification protocol (TRAP) in tumors and matching normal lung tissue samples obtained from 107 consecutive operable patients with pathological stage I NSCLC. Telomerase activity was detected in 66 (62%) of the 107 tumors examined and in none of the corresponding adjacent noncancerous lung tissue samples. Correlation with pathological parameters showed that telomerase activity was associated with histopathological grade (P = 0.0135) but not with tumor size or histological type. Univariate survival curves, estimated using the method of Kaplan and Meier, defined a significant association between telomerase activity and both disease-free survival (P = 0.0115) and overall survival (P = 0.0129). In multivariate analyses, performed by Cox’s proportional hazards regression models, the presence of telomerase activity was the only strong predictor of disease-free survival (P = 0.0173) and overall survival (P = 0.0187). Our data indicate that telomerase activity can be an important prognostic factor that should be considered in future prospective trials of adjuvant therapy for high-risk stage I NSCLC patients.
This article has been cited by other articles:
|
|
 |
|
  T. Matsuo, E. Hiyama, T. Sugita, S. Shimose, T. Kubo, Y. Mochizuki, N. Adachi, K. Kojima, P. Sharman, and M. Ochi Telomerase Activity in Giant Cell Tumors of Bone Ann. Surg. Oncol., October 1, 2007; 14(10): 2896 - 2902. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Bolonaki, A. Kotsakis, E. Papadimitraki, D. Aggouraki, G. Konsolakis, A. Vagia, C. Christophylakis, I. Nikoloudi, E. Magganas, A. Galanis, et al. Vaccination of Patients With Advanced Non-Small-Cell Lung Cancer With an Optimized Cryptic Human Telomerase Reverse Transcriptase Peptide J. Clin. Oncol., July 1, 2007; 25(19): 2727 - 2734. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Nishio, K. Nakanishi, Y. Ozeki, S.-X. Jiang, T. Kameya, A. Hebisawa, M. Mukai, W. D. Travis, T. J. Franks, and T. Kawai Telomere Length, Telomerase Activity, and Expressions of Human Telomerase mRNA Component (hTERC) and Human Telomerase Reverse Transcriptase (hTERT) mRNA in Pulmonary Neuroendocrine Tumors Jpn. J. Clin. Oncol., January 1, 2007; 37(1): 16 - 22. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Brambilla and S. Lantuejoul Telomerase activation in adenocarcinoma-bronchioloalveolar carcinoma. Eur. Respir. J., June 1, 2006; 27(6): 1079 - 1081. [Full Text] [PDF]
|
|
|
|
|
|
F. Suau, V. Cottin, F. Archer, S. Croze, J. Chastang, G. Cordier, F. Thivolet-Bejui, J-F. Mornex, and C. Leroux Telomerase activation in a model of lung adenocarcinoma Eur. Respir. J., June 1, 2006; 27(6): 1175 - 1182. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Dome, C. A. Bockhold, S. M. Li, S. D. Baker, D. M. Green, E. J. Perlman, D. A. Hill, and N. E. Breslow High Telomerase RNA Expression Level Is an Adverse Prognostic Factor for Favorable-Histology Wilms' Tumor J. Clin. Oncol., December 20, 2005; 23(36): 9138 - 9145. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. P. Hsu, J. Miaw, S. E. Shai, and C. Y. Chen Correlation between telomerase expression and terminal restriction fragment length ratio in non-small cell lung cancer--an adjusted measurement and its clinical significance Eur. J. Cardiothorac. Surg., August 1, 2004; 26(2): 425 - 431. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. G. Pfister, D. H. Johnson, C. G. Azzoli, W. Sause, T. J. Smith, S. Baker Jr, J. Olak, D. Stover, J. R. Strawn, A. T. Turrisi, et al. American Society of Clinical Oncology Treatment of Unresectable Non-Small-Cell Lung Cancer Guideline: Update 2003 J. Clin. Oncol., January 15, 2004; 22(2): 330 - 353. [Full Text] [PDF]
|
|
|
|
|
|
D. L. Smith, J.-C. Soria, L. Morat, Q. Yang, L. Sabatier, D. D. Liu, R. A. Nemr, A. Rashid, and J.-N. Vauthey Human Telomerase Reverse Transcriptase (hTERT) and Ki-67 are Better Predictors of Survival than Established Clinical Indicators in Patients Undergoing Curative Hepatic Resection for Colorectal Metastases Ann. Surg. Oncol., January 1, 2004; 11(1): 45 - 51. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Buttitta, C. Pellegrini, A. Marchetti, A. Gadducci, S. Cosio, L. Felicioni, F. Barassi, S. Salvatore, C. Martella, G. Coggi, et al. Human Telomerase Reverse Transcriptase mRNA Expression Assessed by Real-Time Reverse Transcription Polymerase Chain Reaction Predicts Chemosensitivity in Patients With Ovarian Carcinoma J. Clin. Oncol., April 1, 2003; 21(7): 1320 - 1325. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Nakanishi, T. Kawai, F. Kumaki, S. Hiroi, M. Mukai, E. Ikeda, C. E. Koering, and E. Gilson Expression of mRNAs for Telomeric Repeat Binding Factor (TRF)-1 and TRF2 in Atypical Adenomatous Hyperplasia and Adenocarcinoma of the Lung Clin. Cancer Res., March 1, 2003; 9(3): 1105 - 1111. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Dikmen, M. Kara, G. Dikmen, H. Cakmak, and P. Dogan Detection of telomerase activity in bronchial lavage as an adjunct to cytological diagnosis in lung cancer Eur. J. Cardiothorac. Surg., February 1, 2003; 23(2): 194 - 199. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-C. Soria, X. Xu, D. D. Liu, J. J. Lee, J. Kurie, R. C. Morice, F. Khuri, L. Mao, W. K. Hong, and R. Lotan Retinoic Acid Receptor {beta} and Telomerase Catalytic Subunit Expression in Bronchial Epithelium of Heavy Smokers J Natl Cancer Inst, January 15, 2003; 95(2): 165 - 168. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. Brundage, D. Davies, and W. J. Mackillop Prognostic Factors in Non-small Cell Lung Cancer* : A Decade of Progress Chest, September 1, 2002; 122(3): 1037 - 1057. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Wang, J.-C. Soria, B. L. Kemp, D. D. Liu, L. Mao, and F. R. Khuri hTERT Expression Is a Prognostic Factor of Survival in Patients with Stage I Non-Small Cell Lung Cancer Clin. Cancer Res., September 1, 2002; 8(9): 2883 - 2889. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Ohmura, M. Aoe, A. Andou, and N. Shimizu Telomerase Activity and Bcl-2 Expression in Non-Small Cell Lung Cancer Clin. Cancer Res., August 1, 2000; 6(8): 2980 - 2987. [Abstract] [Full Text]
|
|
|
|
|
|
N. Tatsumoto, E. Hiyama, Y. Murakami, Y. Imamura, J. W. Shay, Y. Matsuura, and T. Yokoyama High Telomerase Activity Is an Independent Prognostic Indicator of Poor Outcome in Colorectal Cancer Clin. Cancer Res., July 1, 2000; 6(7): 2696 - 2701. [Abstract] [Full Text]
|
|
|
|
 |
|
 B. Ogretmen, D. Schady, J. Usta, R. Wood, J. M. Kraveka, C. Luberto, H. Birbes, Y. A. Hannun, and L. M. Obeid Role of Ceramide in Mediating the Inhibition of Telomerase Activity in A549 Human Lung Adenocarcinoma Cells J. Biol. Chem., June 29, 2001; 276(27): 24901 - 24910. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
